Patents by Inventor Brian M. Beyer

Brian M. Beyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Lubrication System for a Traction Powertrain
    Publication number: 20240125381
    Abstract: A mobile machine can include a traction powertrain configured to operate on electrical power and which includes a traction motor coupled to a transmission. To lubricate the transmission, the mobile machine can include a lubrication system having a lubricant pump coupled with a pump motor. The traction motor and the pump motor are electrically arranged in parallel with each other. A powertrain sensor monitors rotational motion in the traction powertrain and an electronic controller can generate a lubricant supply command directing the lubricant pump to deliver a first lubricant quantity to the transmission.
    Type: Application
    Filed: October 14, 2022
    Publication date: April 18, 2024
    Applicant: Caterpillar Inc.
    Inventors: Brian E. Lister, Michael D. Beyer, Alex M. Fullenkamp
  • Engineered anti-IL-23p19 antibodies
    Patent number: 9809648
    Abstract: Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: November 7, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Leonard G. Presta, Brian M. Beyer, Richard N. Ingram, Peter Orth, Yan-Hui Liu
  • Factor IXa crystals, related complexes and methods
    Patent number: 8710188
    Abstract: The present invention relates to factor IXa complexes and crystals thereof as well as methods for identifying inhibitors of factor IXa.
    Type: Grant
    Filed: May 31, 2011
    Date of Patent: April 29, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Brian M. Beyer, Alan W. Hruza, Richard N. Ingram, Vincent S. Madison, Andrew J. Prongay, Paul Reichert
  • Engineered anti-IL-23p19 antibodies
    Patent number: 8513389
    Abstract: Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: August 20, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Leonard G. Presta, Brian M. Beyer, Richard N. Ingram, Peter Orth, Yan-Hui Liu
  • Factor IXa Crystals, Related Complexes and Methods
    Publication number: 20130157281
    Abstract: The present invention relates to factor IXa complexes and crystals thereof as well as methods for identifying inhibitors of factor IXa.
    Type: Application
    Filed: May 31, 2011
    Publication date: June 20, 2013
    Applicant: SCHERING CORPORATION
    Inventors: BRIAN M. BEYER, ALAN W. HRUZA, RICHARD N. INGRAM, VINCENT S. MADISON, ANDREW J. PRONGAY, PAUL REICHERT
  • ENGINEERED ANTI-IL-23p19 ANTIBODIES
    Publication number: 20130039916
    Abstract: Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
    Type: Application
    Filed: June 22, 2012
    Publication date: February 14, 2013
    Applicant: Merck Sharpe & Dohme Corp.
    Inventors: Leonard G. Presta, Brian M. Beyer, Richard N. Ingram, Peter Orth, Yan-Hui Liu
  • ASSAY FOR PCSK9 INHIBITORS
    Publication number: 20120214181
    Abstract: The present invention provides methods for identifying modulators of PCSK9, for example, using a variety of assay formats. Inhibitors of PCSK9 can be used for example, to treat diseases such as hyperlipidemia and related disorders.
    Type: Application
    Filed: May 8, 2012
    Publication date: August 23, 2012
    Inventors: Brian M. Beyer, Thomas Hesson, Hung V. Le, Andrew J. Prongay, Krishna Kalghatgi, Jennifer Joanne Gesell, Richard N. Ingram, Michael R. Ziebell
  • Assay for PCSK9 inhibitors
    Patent number: 8206943
    Abstract: The present invention provides methods for identifying modulators of PCSK9, for example, using a variety of assay formats. Inhibitors of PCSK9 can be used for example, to treat diseases such as hyperlipidemia and related disorders.
    Type: Grant
    Filed: June 29, 2009
    Date of Patent: June 26, 2012
    Assignee: Schering Corporation
    Inventors: Brian M. Beyer, Thomas Hesson, Hung V. Le, Andrew J. Prongay, Krishna Kalghatgi, Jennifer Joanne Gesell, Richard N. Ingram, Michael R. Ziebell
  • Refolded recombinant ?-secretase crystals and methods for preparing and using the same
    Patent number: 8063185
    Abstract: The present application relates to methods for growing crystals of both the uncomplexed and complexed forms of ?-secretase (BACE) polypeptide. The present application also relates to crystalline forms of uncomplexed BACE and the three-dimensional structure of BACE, as determined from the crystals. In addition, the present application relates to the use of crystalline forms of BACE to identify ligands, preferably inhibitors (antagonists), which bind to, and preferably inhibit the enzymatic activity of, BACE. Furthermore, the present application relates to nucleic acid sequences encoding BACE polypeptide, and methods for making BACE in greater quantity than prior methods, resulting in more effective crystallization.
    Type: Grant
    Filed: May 4, 2009
    Date of Patent: November 22, 2011
    Assignee: Schering Corp.
    Inventors: Brian M. Beyer, Bruce A. Malcolm, Corey O. Strickland, Wenyan Wang, Eileen Wilson
  • Factor IXa crystals, related complexes and methods
    Patent number: 7968683
    Abstract: The present invention relates to factor IXa complexes and crystals thereof as well as methods for identifying inhibitors of factor IXa.
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: June 28, 2011
    Assignee: Schering Corporation
    Inventors: Brian M. Beyer, Alan W. Hruza, Richard N. Ingram, Vincent S. Madison, Andrew J. Prongay, Paul Reichert
  • Engineered Anti-IL-23p19 Antibodies
    Publication number: 20110142853
    Abstract: Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
    Type: Application
    Filed: February 21, 2011
    Publication date: June 16, 2011
    Applicant: Schering Corporation
    Inventors: Leonard G. Presta, Brian M. Beyer, Richard N. Ingram, Peter Orth, Yan-Hui Liu
  • Engineered Anti-IL-23 Antibodies
    Publication number: 20110002942
    Abstract: Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
    Type: Application
    Filed: September 14, 2010
    Publication date: January 6, 2011
    Applicant: Schering Corporation
    Inventors: Leonard G. Presta, Brian M. Beyer, Richard N. Ingram, Peter Orth, Yan-Hui Liu
  • Modified tumor necrosis factor-alpha converting enzyme and methods of use thereof
    Patent number: 7824897
    Abstract: The present invention discloses a modified tumor necrosis factor-alpha converting enzyme (TACE) catalytic domain, that unlike the native TACE catalytic domain, is stable at high protein concentrations. The present invention further discloses methods for generating crystals of the modified TACE protein in protein-ligand complexes with a number of inhibitors. In addition, the present invention discloses methods of using the proteins, crystals and/or three-dimensional structures obtained to identify compounds that can modulate the enzymatic activity of TACE.
    Type: Grant
    Filed: February 9, 2010
    Date of Patent: November 2, 2010
    Assignee: Schering Corp.
    Inventors: Brian M. Beyer, Richard N. Ingram, Peter Orth, Corey O. Strickland
  • ENGINEERED ANTI-IL-23P19 ANTIBODIES
    Publication number: 20100272731
    Abstract: Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g., in treatment of inflammatory, autoimmune, and proliferative disorders.
    Type: Application
    Filed: February 21, 2008
    Publication date: October 28, 2010
    Inventors: Leonard G. Presta, Brian M. Beyer, Richard N. Ingram, Peter Orth, Yan-Hui Liu
  • Engineered anti-IL-23 antibodies
    Patent number: 7807160
    Abstract: Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
    Type: Grant
    Filed: August 29, 2006
    Date of Patent: October 5, 2010
    Assignee: Schering Corporation
    Inventors: Leonard G. Presta, Brian M. Beyer, Richard N. Ingram, Peter Orth, Yan-Hui Liu
  • REFOLDED RECOMBINANT ALPHA SECRETASE CRYSTALS AND METHODS FOR PREPARING AND USING THE SAME
    Publication number: 20100203616
    Abstract: The present application relates to methods for growing crystals of both the uncomplexed and complexed forms of ?-secretase (BACE) polypeptide. The present application also relates to crystalline forms of uncomplexed BACE and the three-dimensional structure of BACE, as determined from the crystals. In addition, the present application relates to the use of crystalline forms of BACE to identify ligands, preferably inhibitors (antagonists), which bind to, and preferably inhibit the enzymatic activity of, BACE. Furthermore, the present application relates to nucleic acid sequences encoding BACE polypeptide, and methods for making BACE in greater quantity than prior methods, resulting in more effective crystallization.
    Type: Application
    Filed: May 4, 2009
    Publication date: August 12, 2010
    Inventors: Brian M. Beyer, Bruce A. Malcolm, Corey O. Strickland, Wenyan Wang, Eileen Wilson
  • MODIFIED TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME AND METHODS OF USE THEREOF
    Publication number: 20100184111
    Abstract: The present invention discloses a modified tumor necrosis factor-alpha converting enzyme (TACE) catalytic domain, that unlike the native TACE catalytic domain, is stable at high protein concentrations. The present invention further discloses methods for generating crystals of the modified TACE protein in protein-ligand complexes with a number of inhibitors. In addition, the present invention discloses methods of using the proteins, crystals and/or three-dimensional structures obtained to identify compounds that can modulate the enzymatic activity of TACE.
    Type: Application
    Filed: February 9, 2010
    Publication date: July 22, 2010
    Inventors: Brian M. Beyer, Richard N. Ingram, Peter Orth, Corey Strickland
  • ENGINEERED ANTI-IL-23P19 ANTIBODIES
    Publication number: 20100111966
    Abstract: Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
    Type: Application
    Filed: February 21, 2008
    Publication date: May 6, 2010
    Inventors: Leonard G. Presta, Brian M. Beyer, Richard N. Ingram, Peter Orth, Yan-Hui Liu
  • Modified tumor necrosis factor-alpha converting enzyme and methods of use thereof
    Patent number: 7700753
    Abstract: The present invention discloses a modified tumor necrosis factor-alpha converting enzyme (TACE) catalytic domain, that unlike the native TACE catalytic domain, is stable at high protein concentrations. The present invention further discloses methods for generating crystals of the modified TACE protein in protein-ligand complexes with a number of inhibitors. In addition, the present invention discloses methods of using the proteins, crystals and/or three-dimensional structures obtained to identify compounds that can modulate the enzymatic activity of TACE.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: April 20, 2010
    Assignee: Schering Corporation
    Inventors: Brian M. Beyer, Richard N. Ingram, Peter Orth, Corey O. Strickland
  • MODIFIED TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME AND METHODS OF USE THEREOF
    Publication number: 20090221016
    Abstract: The present invention discloses a modified tumor necrosis factor-alpha converting enzyme (TACE) catalytic domain, that unlike the native TACE catalytic domain, is stable at high protein concentrations. The present invention further discloses methods for generating crystals of the modified TACE protein in protein-ligand complexes with a number of inhibitors. In addition, the present invention discloses methods of using the proteins, crystals and/or three-dimensional structures obtained to identify compounds that can modulate the enzymatic activity of TACE.
    Type: Application
    Filed: April 8, 2009
    Publication date: September 3, 2009
    Inventors: Brian M. Beyer, Richard N. Ingram, Peter Orth, Corey Strickland